Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06034561 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Start date changed from estimate of Apr 2024 to Apr 1, 2024v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2023 to Apr 2024
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a interventional phase II study aiming to examine the complete response rate of a bortezomib-based salvage regimen in adults with refractory or relapsed acute lymphoblastic leukemia (ALL), seeking to compare outcomes with the available literature and with our historical data on relapsed/refractory ALL.
Trial Details
NCT Number NCT06034561
Lead Sponsor Instituto do Cancer do Estado de São Paulo
Collaborators: Libbs Farmacêutica LTDA
Conditions
(from sponsor)		 Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
Related terms Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov